Levine Mitchell S 4
4 · Oncocyte Corp · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Levine Mitchell S
Chief Financial Officer
Transactions
- Award
Option to Purchase Common Stock
2022-03-15+87,500→ 87,500 totalExercise: $1.15Exp: 2032-03-15→ Common Stock (87,500 underlying) - Award
Option to Purchase Common Stock
2022-03-15+87,500→ 87,500 totalExercise: $1.15Exp: 2032-03-15→ Common Stock (87,500 underlying)
Footnotes (2)
- [F1]25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
- [F2]Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.